For years, the comparison between tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) had to be inferred from separate trials conducted in different populations with different designs. SURMOUNT-5 changed that. Published in 2025, it was the first randomized, double-blind, head-to-head trial comparing tirzepatide 10–15mg to semaglutide 2.4mg in adults with obesity or overweight without type 2 diabetes — the exact population that drives most Wegovy and Zepbound prescriptions.
SURMOUNT-5: What the Trial Found
The trial enrolled 751 participants with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) who did not have type 2 diabetes. Participants were randomized to tirzepatide (dose-escalated to 10mg or 15mg based on tolerability) or semaglutide 2.4mg weekly. Both groups followed standard dose titration. The primary endpoint was percentage change in body weight from baseline to 72 weeks.
Tirzepatide-treated participants lost 20.2% of body weight on average, compared to 13.7% for semaglutide — a difference of 6.5 percentage points, or approximately 47% greater relative weight loss. This was statistically significant (p < 0.001). Secondary endpoints were similarly favorable for tirzepatide: 93% of tirzepatide participants lost ≥5% of body weight versus 85% on semaglutide; 62% lost ≥20% on tirzepatide versus 32% on semaglutide.
Four Key Evidence Pillars
The First Direct Head-to-Head: Tirzepatide −20.2% vs Semaglutide −13.7%
The SURMOUNT-5 trial demonstrated tirzepatide's superiority over semaglutide across all pre-specified weight loss thresholds at 72 weeks. The proportion reaching ≥25% body weight loss was 32% with tirzepatide versus 16% with semaglutide. Both drugs were generally well-tolerated; discontinuation due to adverse events was 6.6% for tirzepatide and 8.0% for semaglutide. GI side effects were the most common adverse events in both groups during dose escalation, with no meaningful difference in overall GI tolerability between drugs at steady-state doses.
GIP Receptor Agonism: The Extra Lever Tirzepatide Pulls
Tirzepatide is a "twincretin" — a single molecule that acts as a co-agonist at both the GIP (glucose-dependent insulinotropic peptide) and GLP-1 receptors. GIP receptor agonism adds meaningful effects beyond GLP-1 alone: enhanced fat oxidation in adipocytes, reduced adipocyte lipotoxicity, improved insulin secretion synergy with GLP-1, and — critically — reduced GI side effects compared to pure GLP-1 agonism. GIP receptors in the gut appear to dampen the nausea response that limits GLP-1 receptor activation at higher doses. This may explain why tirzepatide patients can tolerate higher effective receptor engagement with comparable GI tolerability to lower-dose semaglutide.
Muscle Preservation: Tirzepatide's Advantage at High Weight Loss
A body composition substudy of the SURMOUNT-1 trial (tirzepatide 15mg) analyzed dual-energy X-ray absorptiometry (DEXA) data to characterize the composition of weight lost. At 72 weeks, participants lost an average of 22.5kg total weight, of which approximately 35% was lean mass and 65% was fat mass — a ratio comparable to or better than bariatric surgery outcomes and superior to historical caloric-restriction data. At the highest weight loss tier (≥25% body weight), tirzepatide maintained this lean mass ratio, suggesting GIP receptor agonism may contribute to muscle preservation through direct anabolic signaling in skeletal muscle, an effect not seen with pure GLP-1 agonists.
SELECT Trial Semaglutide vs SURPASS-CVOT Tirzepatide
Semaglutide currently holds a critical cardiovascular advantage: the SELECT trial (Lincoff et al., 2023, NEJM) demonstrated a 20% reduction in major adverse cardiovascular events (MACE) in non-diabetic adults with obesity and established CVD — the first obesity drug to demonstrate CV benefit in a non-diabetic population. This was the basis for Medicare Part D coverage of Wegovy for patients with obesity and CVD starting January 2026. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) in type 2 diabetes patients was ongoing as of this writing; the obesity-specific CV outcomes trial (SURMOUNT-MMO) is enrolling but results are not yet available. Patients requiring established cardiovascular outcome data should currently favor semaglutide.
Clinical Decision Framework: Wegovy vs Zepbound
Wegovy vs Zepbound — Who Should Choose Which?
- Choose tirzepatide (Zepbound) when: Maximum weight loss is the primary goal; patient needs ≥15–20% body weight reduction to meaningfully address comorbidities; patient does not have established CVD requiring the SELECT cardiovascular outcome data; patient has type 2 diabetes (Mounjaro covered, with superior HbA1c reduction).
- Choose semaglutide (Wegovy) when: Established cardiovascular disease is present and CV outcome data is required; insurance covers Wegovy but not Zepbound; patient previously tolerated Ozempic and is transitioning to the obesity dose; cost differential is significant in the patient's situation.
- Cost (list price, subject to change): Wegovy ~$1,349/month | Zepbound ~$1,059/month. Zepbound is currently less expensive at list price. Savings cards from Eli Lilly (LillyDirect) can reduce Zepbound to ~$550/month for commercially insured patients; Novo Nordisk offers similar programs for Wegovy.
- Insurance coverage: Both are FDA-approved for chronic weight management. Coverage varies widely by plan. Wegovy has more established prior auth pathways due to earlier market entry. Zepbound coverage is rapidly expanding as of 2024–2025.
Wegovy (Semaglutide) Titration
Zepbound (Tirzepatide) Titration
Full Drug Comparison Table
| Drug | Mechanism | Max Dose | Weight Loss (%BW) | Muscle Preservation | FDA Approval | Monthly Cost (List) |
|---|---|---|---|---|---|---|
| Wegovy | GLP-1 agonist | 2.4mg/week | ~13.7–14.9% | Moderate | Obesity; CV risk (SELECT) | ~$1,349 |
| Zepbound | GIP + GLP-1 dual agonist | 15mg/week | ~20.2% | Superior (DEXA data) | Obesity; OSA | ~$1,059 |
| Ozempic | GLP-1 agonist | 2mg/week | ~6–8% | Moderate | T2D; CV risk reduction | ~$800–900 |
| Mounjaro | GIP + GLP-1 dual agonist | 15mg/week | ~20–22% | Superior | T2D | ~$1,000–1,100 |
Muscle Preservation: Why It Matters More Than the Scale
One of the least-discussed risks of any rapid weight loss intervention — whether dietary, surgical, or pharmacological — is sarcopenic obesity: losing fat but also losing significant lean mass, which worsens metabolic outcomes, reduces strength, and accelerates functional decline in older adults. At weight losses exceeding 15% of body weight, preserving muscle becomes a critical clinical priority.
The SURMOUNT-1 body composition data suggest tirzepatide maintains a favorable fat-to-lean mass loss ratio even at high total weight loss. This likely reflects the GIP receptor's anabolic signaling in skeletal muscle — GIP receptors are expressed in muscle tissue and may influence protein synthesis and glucose uptake independent of weight loss effects. Resistance training and adequate protein intake (1.2–1.6g/kg body weight) remain the most evidence-supported interventions for muscle preservation on any weight loss drug.